By Stephen Parmley, Senior
The number of antibody-drug conjugates in development for
cancer is still growing, but most have tubulin
inhibitor payloads that will limit treatment options if resistance emerges.
Heidelberg Pharma GmbH has resurrected a decades-old antibody-drug conjugate
payload that uses a different mode of action, and the company hopes its
extended deal with Roche can lead to clinical
validation. The outcome will likely rest on whether the new technology can
solve the toxicity profile that sank the agent the first time around.